These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
314 related items for PubMed ID: 9102172
1. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. Arterioscler Thromb Vasc Biol; 1997 Mar; 17(3):528-35. PubMed ID: 9102172 [Abstract] [Full Text] [Related]
2. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Schwarz M, Nordt T, Bode C, Peter K. Thromb Res; 2002 Aug 15; 107(3-4):121-8. PubMed ID: 12431477 [Abstract] [Full Text] [Related]
3. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls. Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ. Thromb Haemost; 2000 Feb 15; 83(2):217-23. PubMed ID: 10739376 [Abstract] [Full Text] [Related]
4. Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. Plescia J, Conte MS, VanMeter G, Ambrosini G, Altieri DC. J Biol Chem; 1998 Aug 07; 273(32):20372-7. PubMed ID: 9685389 [Abstract] [Full Text] [Related]
5. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV. Circulation; 1995 Mar 01; 91(5):1354-62. PubMed ID: 7867173 [Abstract] [Full Text] [Related]
6. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. J Am Coll Cardiol; 1995 Dec 01; 26(7):1665-71. PubMed ID: 7594101 [Abstract] [Full Text] [Related]
7. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. J Clin Invest; 1996 Aug 01; 98(3):863-74. PubMed ID: 8698879 [Abstract] [Full Text] [Related]
8. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, Smith CW. J Am Coll Cardiol; 1999 Jan 01; 33(1):97-106. PubMed ID: 9935015 [Abstract] [Full Text] [Related]
9. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Konstantopoulos K, Kamat SG, Schafer AI, Bañez EI, Jordan R, Kleiman NS, Hellums JD. Circulation; 1995 Mar 01; 91(5):1427-31. PubMed ID: 7867183 [Abstract] [Full Text] [Related]
10. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Circulation; 2002 Oct 15; 106(16):2111-7. PubMed ID: 12379582 [Abstract] [Full Text] [Related]
11. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Cancer Res; 2002 May 15; 62(10):2824-33. PubMed ID: 12019160 [Abstract] [Full Text] [Related]
12. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF. Circulation; 1994 Feb 15; 89(2):596-603. PubMed ID: 7508826 [Abstract] [Full Text] [Related]
13. A common epitope on platelet integrin alpha IIb beta 3 (glycoprotein IIbIIIa; CD41b/CD61) and alpha M beta 2 (Mac-1; CDIIb/CD18) detected by a monoclonal antibody. De Nichilo MO, Shafren DR, Carter WM, Berndt MC, Burns GF, Boyd AW. J Immunol; 1996 Jan 01; 156(1):284-8. PubMed ID: 8598475 [Abstract] [Full Text] [Related]
17. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis. Baron JH, Moiseeva EP, de Bono DP, Abrams KR, Gershlick AH. Cardiovasc Res; 2000 Dec 01; 48(3):464-72. PubMed ID: 11090842 [Abstract] [Full Text] [Related]
18. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Christopoulos C, Mackie I, Lahiri A, Machin S. Blood Coagul Fibrinolysis; 1993 Oct 01; 4(5):729-37. PubMed ID: 8292722 [Abstract] [Full Text] [Related]
19. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Circulation; 1998 Sep 15; 98(11):1085-91. PubMed ID: 9736595 [Abstract] [Full Text] [Related]